GlassScriptPhysician profile
Steven H Lin
NPI 1588700744
$104,548.07
in general payments reported to CMS, 2019-2025
11 companies · $8,125 in 2025
The $8,125 reported for 2025 was more than what 96% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $21K · 2021: $14K · 2022: $10K · 2023: $15K · 2024: $6,683 · 2025: $8,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $14K · Consulting Fee: $13K · Honoraria: $2,073 · Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $13,588.69 |
| Consulting Fee | $12,575.00 |
| Honoraria | $2,072.81 |
| Food and Beverage | $1,155.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $49,497.47 | 2019-2025 | Imfinzi, Tagrisso |
| Astrazeneca Uk Limited | $32,435.14 | 2019-2023 | |
| Siemens Medical Solutions USA, INC. | $8,534.04 | 2024-2025 | Truebeam |
| Elekta Limited | $5,292.70 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $4,979.50 | 2021-2025 | Keytruda |
| Iba Proton Therapy, INC. | $2,072.81 | 2025 | |
| Viewray Technologies INC | $1,477.19 | 2022 | |
| Novocure INC. | $158.26 | 2025 | Optune Lua (Novottf-200t) |
| Tesaro, INC. | $61.03 | 2019 | |
| Telix Pharmaceuticals | $39.93 | 2024 | Illuccix |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.